Genetic Considerations in the Evolving Treatment Landscape of Hormone-Sensitive and Hormone-Resistant Prostate Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 83
Special Issue Editor
Interests: prostate cancer; diagnosis; oncology; statistic; R project for statistical computing; biomarker
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The treatment landscape for hormone-sensitive prostate cancer (HSPC) has evolved rapidly in recent years, with the aim of achieving long-lasting or durable disease control. This is crucial in enhancing the quality of life of affected patients. Historically, the standard of care involved simple androgen deprivation therapy (ADT) using luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. However, since 2015, the therapeutic approach has advanced, introducing the use of Docetaxel as an initial dual therapy with ADT and later incorporating combination therapies with androgen receptor axis-targeted therapy agents (ARATs) such as abiraterone, enzalutamide, apalutamide, and talazoparib. Furthermore, triplet therapies (PEACE-1: abiraterone; ARASENS: darolutamide; + docetaxel +ADT) have emerged as additional treatment options for HSPC. Clinical trials such as STAMPEDE have demonstrated significant improvements in survival for patients with metastatic hormone-sensitive prostate cancer (mHSPC) through the use of targeted therapies such as local radiotherapy. Similarly, cytoreductive radical prostatectomy has been shown to provide a survival advantage in this patient population. The transition to hormone-resistant prostate cancer (HRPC) represents a critical juncture in the disease trajectory, emphasizing the need for the development of improved targeted therapies and enhanced genetic characterization. However, the selection of the optimal therapy for each individual patient remains a challenging task due to the multitude of available options. Genetic profiling through tissue and liquid biopsies is gaining recognition as it contributes to a deeper understanding of the underlying biology and may lead to the more precise and personalized selection of therapy. It is hoped that further advancements in personalized medicine will significantly enhance the treatment outcomes and quality of life for patients with HSPC and HRPC.
Dr. Pierre Tennstedt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- hormone-sensitive prostate cancer, HSPC
- hormone-resistant prostate cancer, HRPC
- metastasis
- androgen deprivation therapy
- docetaxel
- androgen receptor axis-targeted therapy agents, ARAT
- abiraterone
- enzalutamide
- apalutamide
- talazoparib
- genetic
- biomarker
- liquid biopsy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
